ETBX-71 Vaccine

Phase 2

NNational Cancer Institute (NCI)

ETBX-71 Vaccine is one of 2 therapeutic programs targeting Recurrent Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent Prostate CancerNot yet recruiting

Recurrent Prostate CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Recurrent Prostate Cancer

#DrugCompanyPhaseTrials

N-803

IImmunityBio, Inc.

Phase 2

1 2

ETBX-71 Vaccine

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Not yet recruiting

Recurrent Prostate Cancer

NCT07686380

Clinical

Trials by Indication[1]

Recurrent Prostate Cancer1 trial

Phase II Trial of IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07686380·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ETBX-71 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ETBX-71 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

ETBX-71 Vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Recurrent Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News